US biopharmaceutical company Hoth Therapeutics Inc (NASDAQ: HOTH) announced on Tuesday that GW University Hospital, UC Irvine and Northwell Health have provided written approval to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 intended for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

The Phase 2a dose-ranging study is intended to assess the efficacy, safety and tolerability of topical HT-001 intended for the treatment of skin toxicities related to EGFRi.

Hoth Therapeutics chief executive officer Robb Knie said: "We are very pleased to have received approval from these three world class medical centres for our FIH clinical trial. We are hopeful that this trial will demonstrate successful delivery of our lead therapeutic candidate HT-001 and bring hope to cancer patients suffering from skin toxicities associated with EGFRi treatments."